Efavirenz/lamivudine/tenofovir disoproxil fumarate - Cipla

Drug Profile

Efavirenz/lamivudine/tenofovir disoproxil fumarate - Cipla

Alternative Names: Efavirenz 600mg/lamivudine 300mg/tenofovir disoproxil fumarate 300mg - Cipla; Efavirenz/tenofovir disoproxil fumarate/lamivudine - Cipla; Lamivudine/efavirenz/tenofovir disoproxil fumarate - Cipla; Lamivudine/tenofovir disoproxil fumarate/efavirenz - Cipla; Tenofovir disoproxil fumarate/efavirenz/lamivudine - Cipla; Trioday

Latest Information Update: 24 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cipla
  • Class Antiretrovirals; Benzoxazines; Deoxyribonucleosides; Dideoxynucleosides; Phosphonic acids; Purines; Pyrimidine nucleosides
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top